| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,823,000 |
| Market
Cap: |
1.89(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.92 - $29.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 484 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
60,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$980,094 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
20,000 |
20,000 |
104,169 |
535,146 |
| Total Sell Value |
$460,127 |
$460,127 |
$2,968,197 |
$14,025,264 |
| Total People Sold |
2 |
2 |
4 |
8 |
| Total Sell Transactions |
2 |
2 |
12 |
30 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kennedy Keith |
COO / CFO |
• – – |
2020-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
300 |
158,307 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• – – |
2020-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
265 |
74,849 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-05-11 |
4 |
AS |
$26.66 |
$533,334 |
D/D |
(20,000) |
274,183 |
|
17% |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-05-11 |
4 |
OE |
$4.00 |
$80,000 |
D/D |
20,000 |
294,183 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,870 |
274,183 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-03-20 |
4 |
OE |
$2.68 |
$42,880 |
D/D |
16,000 |
272,313 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-03-10 |
4 |
AS |
$25.18 |
$503,520 |
D/D |
(20,000) |
256,313 |
|
25% |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-03-10 |
4 |
OE |
$4.00 |
$80,000 |
D/D |
20,000 |
276,313 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2020-03-03 |
4 |
AS |
$25.35 |
$834,798 |
D/D |
(32,881) |
81,274 |
|
14% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2020-03-03 |
4 |
OE |
$5.43 |
$107,111 |
D/D |
15,033 |
114,155 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• – – |
2020-03-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,888) |
74,584 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2020-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,393) |
158,007 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• – – |
2020-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(997) |
77,472 |
|
- |
|
| Ho Mark |
Principal Accounting Officer |
– – – |
2020-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(486) |
25,419 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,937) |
256,313 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2020-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(896) |
99,122 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
159,400 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• – – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
78,469 |
|
- |
|
| Ho Mark |
Principal Accounting Officer |
– – – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
25,905 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
261,250 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
100,018 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2020-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(8,844) |
88,018 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2020-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
96,862 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(39,488) |
228,250 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
267,738 |
|
- |
|
524 Records found
|
|
Page 12 of 21 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.52 (2.22%) 
